Wednesday, July 8, 2026

pharma · Prostate Cancer · Autoimmune · JANX

Janux Therapeutics

Janux Therapeutics patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

San Diego, USA HQ
2017 Founded
110 Employees
Public company Type
JANX · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2017
Employees
110
Programs
4
Drugs
0
Patents
2
Intelligence · Patents

Janux Therapeutics patents

2 pharmaceutical patents indexed for Janux Therapeutics. 0 expire within 24 months.

Janux Therapeutics has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12161724

    Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11512113

    Cleavable linker compositions and methods

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Janux Therapeutics have?

2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Janux Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.